On 26 August 2026, Singapore’s Health Sciences Authority instructed the recall of two batches of Medicube’s PDRN Pink Collagen Capsule Cream after testing detected minute amounts of Sudan IV — a prohibited industrial dye — in product samples sold by a local retailer. HSA instructed the recall of these affected batches on 26 August 2026 and has required all three companies marketing the product in Singapore to ensure every future batch is tested by an accredited laboratory for the absence of Sudan IV before local supply.
Medicube is one of the most recognisable Korean skincare brands in Singapore right now. The PDRN Pink Collagen Capsule Cream is among its most viral products. And the banned substance found in it is not an exotic or obscure chemical. It is an industrial dye used in petroleum products, shoe polish, and motor oil — with documented carcinogenic and allergenic properties — that has no legitimate place in a cosmetic product at any concentration.
This is worth paying attention to. Not to alarm people who have already used the product — HSA confirmed the quantities detected are minute and unlikely to pose serious health risks from previous use. But to understand what this incident reveals about how a banned ingredient can appear in a legitimate, popular, well-distributed product — and why the checks that prevent this matter more than most consumers realise.
What Sudan Red is and why it is banned
Sudan Red dyes are a family of industrial synthetic dyes — Sudan I, II, III, and IV — originally developed for colouring petroleum products, waxes, oils, and shoe polish. They are not cosmetic ingredients. They have never been approved for cosmetic use in Singapore, the EU, the US, or most regulated markets. Sudan Red refers to a group of industrial dyes with potential health risks because of possible carcinogenic and allergenic properties.
Sudan IV specifically — the compound detected in the recalled Medicube batches — is classified as a possible human carcinogen. It has no cosmetic function. There is no reason for it to be in a skincare product either as an active ingredient or as a legitimate manufacturing input. Its presence in a cosmetic is either contamination from an impure raw material, cross-contamination in a manufacturing facility, or deliberate adulteration.
How a banned substance ends up in a legitimate product
The most important thing to understand about this incident is that Sudan IV was not detected in batches supplied directly by Medicube’s own Singapore subsidiary (APR SG Pte. Ltd.) or by wholesaler Rirora International. Sudan IV was detected only in two samples of the product sold by Venus Beauty Pte. Ltd. — a separate local retailer distributing the same product from different batch sources.
This distinction matters significantly. The leading explanations for how a banned industrial dye appears in two specific batches of an otherwise compliant product are:
Raw material contamination. It is possible that contamination or adulteration of a raw material, cross-contamination, a batch difference, sample authenticity or analytical method differences contributed to the detection of Sudan Red in Medicube PDRN Pink Collagen Cream. A raw material supplier providing a pigment, colorant, or another ingredient at a lower purity grade or contaminated from an industrial source could introduce trace Sudan dye into a formula without the brand’s knowledge. This is the most common route for banned substances to enter legitimate product supply chains.
Counterfeit or adulterated product in the distribution chain. When a popular product is distributed through multiple channels — the brand’s own subsidiary, official wholesalers, and third-party retailers — the risk that counterfeit or adulterated batches enter the supply chain through some channels but not others is real. A third-party retailer sourcing product through informal channels rather than directly from the manufacturer may receive batches that are counterfeit, diverted, or adulterated. The banned substance enters not in the original formula but in a fake or tampered batch that moves through retail channels alongside legitimate product.
The fact that checks found the product still available on Shopee and Lazada after HSA had instructed a recall is a direct consequence of how distributed and informal online retail channels operate. A recall instruction reaches authorised distributors. It does not automatically remove a listing from a marketplace seller who sourced product from a grey market or counterfeit source.
Why this is not an isolated problem
The Medicube recall is the most prominent recent case, but the underlying dynamic is not unusual. The number of illegal health products seized by Singapore authorities surged from 737,000 units in 2022 to over 1.12 million units in 2023 — an increase of more than 50 percent. Over 12,000 listings from local e-commerce and social media platforms were removed, three times higher than the year prior. These products were unregistered, counterfeit, or had potent medicinal ingredients and banned substances illegally added.
The common thread across these cases is that consumers purchasing through informal channels — marketplace sellers without clear supply chain accountability, social media shops, group buys, and grey market imports — are buying products for which the regulatory checks that apply to authorised distribution simply do not exist. The brand on the label may be legitimate. The product in the bottle may not be.
What HSA notification and compliance actually means
Cosmetic products sold in Singapore are required to be notified to the HSA before they can be supplied locally. This notification system requires the responsible person to confirm that the product complies with the ASEAN Cosmetic Directive — including the prohibited ingredients list that bans Sudan Red dyes, mercury, hydroquinone above regulated limits, and hundreds of other restricted substances.
It is important to understand exactly what this means and what it does not mean. HSA stressed that product notification is not a form of pre-market approval and should not be construed as product certification or registration by the agency. Notification means the brand has declared compliance. It does not mean HSA has independently tested and verified that every batch of every notified product is free of prohibited substances.
What notification does create is accountability and traceability. A notified product has a responsible person on record who is legally accountable for its compliance. When HSA detects a prohibited substance, it can act quickly — instruction to recall, requirement for batch testing before any future local supply, potential enforcement action against the responsible person. This accountability structure is what allows the Medicube situation to move from detection to recall instruction within weeks rather than months.
For unnotified products — those being sold through informal channels, grey market imports, or counterfeit sources — there is no responsible person on record, no legal accountability structure, and no mechanism for a rapid regulated recall. The consumer buying an unnotified product from a Shopee seller has no recourse when the product contains a banned substance, because there is no registered party to hold accountable.
AURA is HSA-notified
AURA LIFT and AURA Bright are both notified with the HSA under Singapore’s Health Products (Cosmetic Products – ASEAN Cosmetic Directive) Regulations. This means:
- Every active and inactive ingredient in both formulas has been disclosed to HSA and confirmed as compliant with the prohibited ingredients list
- There is a legally accountable responsible person on record for both products in Singapore
- AURA is subject to HSA’s post-market surveillance and enforcement framework, meaning if a compliance issue were ever detected, HSA has the regulatory authority and the accountability structure to act
- The ingredient transparency AURA publishes — full INCI lists at go-aura.co/products/pl-aura-lifter-serum and go-aura.co/products/aura-bright-pigmentation-and-uneven-skin-tone — is consistent with the formulas declared to HSA. What is on the label is what is in the bottle
HSA notification is not a marketing claim. It is a regulatory baseline that separates products with supply chain accountability from those without. In the context of what the Medicube situation has demonstrated — that banned substances can enter distribution chains through raw material contamination or counterfeit product even for well-known brands — the question of whether a product has a legally accountable responsible person in Singapore’s regulatory system is not a bureaucratic detail. It is the mechanism that determines whether you have any protection when something goes wrong.
What to check before buying any skincare product in Singapore
The Medicube incident provides a practical checklist for evaluating any skincare purchase in Singapore:
Is the product sold by an authorised distributor? The same product sold by the brand’s own local subsidiary and by a third-party marketplace seller may not be from the same source. Authorised distributors source directly from the manufacturer. Marketplace sellers may source from grey market channels where batch provenance is not guaranteed.
Is it available for a suspiciously low price? Popular K-beauty products with strong consumer demand attract counterfeit supply. A listing significantly below the authorised retail price is a signal that the supply chain is not the authorised one — and that the product in the listing may not be the product it claims to be.
Can you verify the HSA notification? HSA maintains a searchable database of notified cosmetic products at hsa.gov.sg. If a product is not findable in the notification database, it either has not been notified (and therefore lacks the accountability structure of regulated supply) or is being sold under a different name from its notified version.
Is the full ingredient list published and verifiable? A brand that publishes its full INCI list and explains what each ingredient does has made a commitment to transparency that is harder to maintain while also including undisclosed banned substances. AURA publishes the full INCI for both products precisely because ingredient transparency and regulatory compliance are the same commitment, not separate ones.
The Medicube situation is not a scandal about Medicube specifically. It is a reminder of what the skincare supply chain in Singapore actually looks like and where the gaps in consumer protection exist.
A well-known brand’s product moving through multiple distribution channels, some authorised and some not, with batch-level quality variation that regulatory testing catches after the product is already in consumers’ hands — this is the normal operating condition of the Singapore skincare market. The protection against it is not brand recognition. It is HSA notification, authorised distribution, supply chain accountability, and ingredient transparency. Those are the things worth checking before you buy.
AURA LIFT and AURA Bright are both HSA-notified cosmetic products.
Full ingredient lists are published for both. Formulated in Korean and Japanese laboratories. Sold through our own authorised channel only.
0 nhận xét